InsidersTradesSigma
Track the Cryoport, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Industry sector, Cryoport, Inc. has recorded 95 insider filings. Market capitalisation: €762.1m. The latest transaction was filed on 11 August 2026 (Cession). Among the most active insiders: SHELTON JERRELL. All data is openly available.
95
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€2m
27 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Cryoport, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$17.67.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,931 of 29,062 companies
59.4
score / 100
Value58
Quality61
FCF yld-3.4%
Earn yld9.6%
EV/EBITDA·
ROE-6.5%
Gross mgn47%
Net mgn44%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 August 2026
Declarations95 total
28,800 shares@ US$14.9092Common StockSEC:0001104659-26-094228:0
33,600 shares@ US$14.47140.059% mcap100.0% of flowCommonSEC144:0001950047-26-005914
1,400 shares@ US$15.23140.0027% mcap4.2% of flowCommonSEC144:0001950047-26-005868
23,214 shares@ US$15.44120.045% mcap100.0% of flowCommonSEC144:0001950047-26-005741
169,427 shares@ US$16.500.35% mcap80.0% of flowCommonSEC144:0001973097-26-000017
22,845 shares0Common StockSEC:0001104659-26-029718:0
7,918 shares@ US$8.002.2% of flowCommon StockSEC:0001104659-26-029719:0
21,322 shares0Common StockSEC:0001104659-26-029720:0
87,188 shares@ US$1.8726.5% of flowCommon StockSEC:0001104659-26-028775:0
11,570 shares@ US$9.986223.8% of flowCommon StockSEC:0001104659-25-120727:0
50,000 shares@ US$2.6629.9% of flowCommon StockSEC:0001104659-25-089633:0
5,000 shares@ US$8.6013.9% of flowCommon StockSEC:0001104659-25-085826:0
26,164 shares@ US$3.0711.5% of flowCommon StockSEC:0001104659-25-081460:0
25,000 shares@ US$5.004.3% of flowCommon StockSEC:0001104659-25-079308:0
25,000 shares@ US$5.004.6% of flowCommon StockSEC:0001104659-25-073737:0
25,000 shares@ US$5.004.7% of flowCommon StockSEC:0001104659-25-071212:0
60,000 shares@ US$3.0749.5% of flowCommon StockSEC:0001104659-25-070419:0
25,000 shares@ US$5.006.3% of flowCommon StockSEC:0001104659-25-069643:0
50,000 shares@ US$5.0010.2% of flowCommon StockSEC:0001104659-25-061279:0
8,193 shares@ US$7.056731.3% of flowCommon StockSEC:0001104659-25-059506:0
23,214 shares0Common StockSEC:0001104659-25-058269:0
23,214 shares0Common StockSEC:0001104659-25-058268:0
23,214 shares0Common StockSEC:0001104659-25-058267:0
75,000 shares@ US$3.0782.5% of flowCommon StockSEC:0001104659-25-058270:0
23,214 shares0Common StockSEC:0001104659-25-058266:0
25 of 95 declarations
关于 Cryoport, Inc.
Cryoport, Inc. (NASDAQ: CYRX) 是一家专业的生命科学供应链公司，总部位于美国田纳西州布伦特伍德。公司成立于 1999 年，已从一家以物流为重点的企业发展成为一个综合平台，服务于生物制药、动物保健和人类生殖医学市场。对于投资者而言，Cryoport 不应被视为传统的运输商，而应被视为对温度敏感和高价值生物产品至关重要的基础设施。 公司的核心业务围绕温控物流、低温和超低温运输系统、生物储存以及先进疗法相关服务。其平台支持细胞和基因疗法开发商、生物制剂制造商、临床试验项目以及其他敏感的生命科学应用。随着时间的推移，Cryoport 已将其服务范围从运输扩展到冷冻保存、生物储存、包装、贴标、试剂盒生产和物流协调。这种更广泛的范围增加了钱包份额，并使公司更深入地融入客户工作流程。 Cryoport 的竞争定位建立在专业化、合规性和运营可靠性之上。在先进疗法领域，产品完整性和监管链至关重要，公司在受监管的温控供应链方面的专业知识构成了有意义的进入壁垒。其价值主张在于为运行复杂全球项目的客户降低风险，尤其是在细胞和基因疗法领域，物流故障可能会毁掉一批高价值产品。该集团强调其在美洲、欧洲、中东和非洲以及亚太地区的全球覆盖，拥有 50 多个战略地点和全球超过 3,000 家客户。 最近的发展突显了公司的战略扩张。2024 年 6 月，Cryoport 正式在英国斯蒂夫尼奇启动了其全球供应链中心，加强了其在欧洲的业务。2025 年 1 月，公司宣布与 Moffitt Cancer Center 建立战略合作伙伴关系，在佛罗里达州建立一个最先进的生物储存中心。其 2024 年年度报告还显示，其核心市场持续增长，截至 2024 年底，全球支持了 701 项临床试验，其中包括 81 项 3 期试验。更广泛地说，Cryoport 仍然是一个以增长为导向的平台，受益于先进疗法的扩展，但其投资案例取决于执行力、细胞和基因疗法的商业应用以及公司将其国际足迹转化为持久盈利的能力。
